التفاصيل البيبلوغرافية
| العنوان: |
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma. |
| المؤلفون: |
Ip, Andrew, Petrillo, Alessandra, Pia, Alexandra Della, Lee, Geeny G., Gill, Sarvarinder, Varughese, Tony, Zenreich, Joshua, Gutierrez, Martin, Zhang, Jiayu, Ahn, Jaeil, Bharani, Vishnu, Nejad, Ava S., Pascual, Lauren, Feldman, Tatyana A., Leslie, Lori A., Goy, Andre H. |
| المصدر: |
Leukemia & Lymphoma; Dec2023, Vol. 64 Issue 14, p2225-2235, 11p |
| مصطلحات موضوعية: |
LENALIDOMIDE, RITUXIMAB, NON-Hodgkin's lymphoma, EXANTHEMA |
| مستخلص: |
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n=25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1–21) and ibrutinib 560mg (days 1–28) of 28-day cycles. The MTD for lenalidomide was 20mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67>30%). R2I was safe and tolerable in patients with R/R MCL. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
